The TRPV1 receptor: target of toxicants and therapeutics.
Understanding the structural and functional complexities of the transient receptor potential vanilloid receptor (TRPV1) is essential to the therapeutic modulation of inflammation and pain. Because of its central role in initiating inflammatory processes and integrating painful stimuli, there is an understandable interest in its pharmacological manipulation (sensitization/desensitization). The present Highlight entitled "TRPV1 antagonists elevate cell surface populations of receptor protein and exacerbate TRPV1 mediated toxicities in human lung epithelial cells" describes how exposure to various antagonists produces TRPV1 sensitization and proposes a possible mechanistic explanation to that sensitization.
Veronesi
Bellina
B
National Health and Environmental Effects Research Laboratory, U.S. Environmental Protection Agency, Neurotoxicology Division--Cellular and Molecular Branch, Research Triangle Park, North Carolina 27711, USA. veronesi.bellina@epa.gov
Oortgiesen
Marga
M
D002460:Cell Line; D004847:Epithelial Cells / Q000187:drug effects / Q000378:metabolism; D006801:Humans; D020078:Neurogenic Inflammation / Q000378:metabolism; D004364:Pharmaceutical Preparations; D050916:TRPV Cation Channels / Q000819:agonists* / Q000037:antagonists & inhibitors* / Q000378:metabolism; D015262:Xenobiotics / Q000494:pharmacology*
D004364:Pharmaceutical Preparations; D050916:TRPV Cation Channels; C494484:TRPV1 receptor; D015262:Xenobiotics